New hope for duchenne: Long-Term safety trial of WVE-N531 underway
NCT ID NCT07209332
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 29 times
Summary
This study looks at the long-term safety of an experimental drug called WVE-N531 in people with Duchenne muscular dystrophy who have already taken it in a previous study. About 175 participants will receive the drug and be monitored for side effects, heart and lung function, and physical abilities like walking and climbing stairs. The goal is to see if the drug remains safe and tolerable over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Istiklal Hospital/ Clinical Research Unit
Amman, Jordan
-
Oxford Children's Hospital, Oxford University Hospitals NHS Foundation Trust
Headington, Oxford, OX3 9DU, United Kingdom
-
The Specialty Hospital (TSH)/ Advanced Clinical Center
Amman, Jordan
Conditions
Explore the condition pages connected to this study.